Browsing by Author "K. Venugopal"

Now showing 1 - 4 of 4

Corrigendum to “Cardiological Society of India position statement on management of heart failure in India” (Indian Heart Journal (2018) 70(S1) (S1–S72), (S0019483218303006) (10.1016/j.ihj.2018.05.003))
(Elsevier B.V., 2018) Santanu Guha; S. Harikrishnan; Saumitra Ray; Rishi Sethi; S. Ramakrishnan; Suvro Banerjee; V.K. Bahl; K.C. Goswami; Amal Kumar Banerjee; S. Shanmugasundaram; P.G. Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U. Mahajan; P.P. Mohanan; Sundeep Mishra; P.K. Deb; C. Narasimhan; A.K. Pancholia; Ajay Sinha; Akshyaya Pradhan; R. Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B.C. Srinivas; B.P. Chattopadhyay; B.P. Singh; J. Balachandar; K.R. Balakrishnan; Brian Pinto; C.N. Manjunath; Charan P. Lanjewar; Dharmendra Jain; Dipak Sarma; G. Justin Paul; Geevar A. Zachariah; H.K. Chopra; I.B. Vijayalakshmi; J.A. Tharakan; J.J. Dalal; J.P.S. Sawhney; Jayanta Saha; Johann Christopher; K.K. Talwar; K. Sarat Chandra; K. Venugopal; Kajal Ganguly; M.S. Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V. Deshpande; O.P. Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S. Somasundaram; S.N. Routray; S.S. Iyengar; G. Sanjay; Satyendra Tewari; G. Sengottuvelu; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U.C. Samal; U. Kaul; V.K. Chopra; V.S. Narain; Vimal Raj; Yash Lokhandwala
In the article titled ‘Cardiological Society of India Position Statement on Management of Heart Failure in India’ below is the list of corrections to be included. The authors would like to apologise for any inconvenience caused. Fig. 14 ECG of a patient with RVEMF and atrial fibrillation, qR in V1 and R/S ratio in lead V2 more than V1. Fig. 15 ECG of a patient with LVEMF showing LVH with strain pattern. Fig. 16. Fluoroscopy showing the presence of LV apical calcium. Fig. 17. LV angiogram in a patient with LVEMF showing the obliteration of the LV apex, transverse diameter more than the longitudinal diameter and no MR (primary diastolic HF). Fig. 18. RV angiogram in a patient with RVEMF showing obliteration of the RV apex and body, RVOF dilatation and significant TR. Fig. 19. Echocardiogram, apical 4-chamber view, showing the presence of calcium at the LV apex. Fig. 20. Perfusion MRI, 4-chamber view in diastole showing fibrosis and obliteration of RV apex (white arrow) [RV – right ventricle, RA – Right atrium, LA – left atrium]. In the text – Page S 48 Column 2 Section 3.10.3 Figs. 13 and 14 – Corrected as Figs. 14 and 15. Figs. 16–18 – Corrected as Figs. 16–19. Fig 19 – Corrected as Fig 20 References: The references are changed as given below (Page S 66). 240. K Balakrishnan, Ratnagiri R, S. Rao, M. Tungaturu Limiting the Number of Endomyocardial Biopsies does not impact one year survival after Heart Transplant. J heart Lung Transplant. Supplement. April 2016 Volume 35; Issue 4, Supplement: S210. 241. Stehlik J, Starling RC, Movsesian MA, et al. Utility of long-term surveillance endomyocardial biopsy: a multi-institutional analysis. J Heart Lung Transplant. 2006; 25:1402–1409. To be added at the end of references (Can be given as reference in the heading 2.8). Status of Cardiac Transplantation in India.(583) 583. Dr KR Balakrishnan, R Ravi Kumar; - “Status of Cardiac Transplantation in India” Pages 599–606 in Chapter 44 of CSI TEXT BOOK OF CARDIOLOGY. (Ed) PK Deb 2018 Jaypee Brothers, New Delhi. © 2018 Cardiological Society of India
CSI position statement on management of heart failure in India
(Elsevier B.V., 2018) Santanu Guha; S. Harikrishnan; Saumitra Ray; Rishi Sethi; S. Ramakrishnan; Suvro Banerjee; V.K. Bahl; K.C. Goswami; Amal Kumar Banerjee; S. Shanmugasundaram; P.G. Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U. Mahajan; P.P. Mohanan; Sundeep Mishra; P.K. Deb; C. Narasimhan; A.K. Pancholia; Ajay Sinha; Akshyaya Pradhan; R. Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B.C. Srinivas; B.P. Chattopadhyay; B.P. Singh; J. Balachandar; K.R. Balakrishnan; Brian Pinto; C.N. Manjunath; Charan P. Lanjewar; Dharmendra Jain; Dipak Sarma; G. Justin Paul; Geevar A. Zachariah; H.K. Chopra; I.B. Vijayalakshmi; J.A. Tharakan; J.J. Dalal; J.P.S. Sawhney; Jayanta Saha; Johann Christopher; K.K. Talwar; K. Sarat Chandra; K. Venugopal; Kajal Ganguly; M.S. Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V. Deshpande; O.P. Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S. Somasundaram; S.N. Routray; S.S. Iyengar; G. Sanjay; Satyendra Tewari; G. Sengottuvelu; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U.C. Samal; U. Kaul; V.K. Chopra; V.S. Narain; Vimal Raj; Yash Lokhandwala
[No abstract available]
The Power and Promise of Angiotensin Receptor Neprilysin Inhibitor (ARNI) in Heart Failure Management: National Consensus Statement
(Journal of Association of Physicians of India, 2023) H.K. Chopra; G.S. Wander; C.K. Ponde; Navin C. Nanda; Dinesh Khullar; K. Venugopal; Saumitra Ray; Tiny Nair; D.S. Rana; Vijay Kher; J.P.S. Sawhney; R.R. Kasliwa; A. Jabir; Rabin Chakraborty; Praveen Chandra; Sandeep Bansal; Viveka Kumar; A.K. Pancholia; Aditya Kapoor; Sunil Prakash; Anil Saxena; Vishal Rastogi; Vinod Sharma; Y.K. Arora; Arup Dasbiswas; Mohan Bhargava; Aparna Jaswal; K. Bhargava; Mona Bhatia; A.K. Omar; N.N. Khanna; Rajiv Passey; Dilip Bhalla; I.B. Vijayalakshmi; A.K. Bhalla; Asha Moorthy; H.S. Isser; S.S. Mishra; S.N. Routray; Vivek Tandon; Ajay Sinha; Manish Bansal; Praveen Jain; Ramesh Hotchandani; Dharmendra Jain; V.K. Katyal; Sanjiv Gulati; Rohit Tandon; Shalini Jaggi; Blessy Sehgal; Vitull Gupta; Rahul Mehrotra; N.C. Krishnamani; S.N. Pathak; M.S. Yadav; Rajeev Chawla; Jyotirmoy Pal; Nandini Chatterjee; Shambo S. Samajdar; N.R. Shastry
Heart failure (HF) is a huge global public health task due to morbidity, mortality, disturbed quality of life, and major economic burden. It is an area of active research and newer treatment strategies are evolving. Recently angiotensin receptor-neprilysin inhibitor (ARNI), a class of drugs (the first agent in this class, Sacubitril–Valsartan), reduces cardiovascular mortality and morbidity in chronic HF patients with reduced left ventricular ejection fraction (LVEF). Positive therapeutic effects have led to a decrease in cardiovascular mortality and HF hospitalizations (HFH), with a favorable safety profile, and have been documented in several clinical studies with an unquestionable survival benefit with ARNI, Sacubitril–Valsartan. This consensus statement of the Indian group of experts in cardiology, nephrology, and diabetes provides a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of the use of ARNI as an essential treatment strategy for HF patients in clinical practice. Consensus in this review favors an early utility of Sacubitril–Valsartan in patients with HF with reduced EF (HFrEF), regardless of the previous therapy being given. A lower rate of hospitalizations for HF with Sacubitril–Valsartan in HF patients with preserved EF who are phenotypically heterogeneous suggests possible benefits of ARNI in patients having 40–50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk. © 2023 Journal of Association of Physicians of India. All rights reserved.
The Promise of Cilnidipine in Hypertension with Comorbidities: National Consensus Statement
(Journal of Association of Physicians of India, 2024) Hirday Kumar Chopra; Gurpreet S. Wander; Chandrashekhar K. Ponde; Navin C. Nanda; Dinesh Khullar; K. Venugopal; Saumitra Ray; Tiny Nair; D.S. Rana; Vijay Kher; J.P.S. Sawhney; R.R. Kasliwal; Jabir Abdullakutty; Rabin Chakraborty; Praveen Chandra; Sandeep Bansal; Viveka Kumar; Arvind K. Pancholia; Aditya Kapoor; Sunil Prakash; Anil Saxena; Vishal Rastogi; Vinod Sharma; Y.K. Arora; Arup Dasbiswas; Mohan Bhargava; Aparna Jaswal; Kartikeya Bhargava; Mona Bhatia; Ashok K. Omar; Narendra Nath Khanna; Rajiv Passey; Dilip Bhalla; I.B. Vijayalakshmi; Anil Kumar Bhalla; Asha Moorthy; Harmohander S. Isser; S.S. Mishra; Satyanarayan Routray; Vivek Tandon; Ajay Sinha; Manish Bansal; Praveen Jain; Ramesh Hotchandani; Dharmendra Jain; V.K. Katyal; Sanjiv Gulati; Rohit Tandon; Shalini Jaggi; Blessy Sehgal; Vitull Gupta; Rahul Mehrotra; N.C. Krishnamani; S.N. Pathak; M.S. Yadav; Rajeev Chawla; N.R. Shastry; Nandini Chatterjee; Shambo Samrat Samajdar; Jyotirmoy Pal; Mangesh Tiwaskar
The rapidly increasing burden of hypertension is responsible for premature deaths from cardiovascular disease (CVD), renal disease, and stroke, with a tremendous public health and financial burden. Hypertension detection, treatment, and control vary worldwide; it is still low, particularly in low- and middle-income countries (LMICs). High blood pressure (BP) and CVD risk have a strong, linear, and independent association. They contribute to alarming numbers of all-cause and CVD deaths. A major culprit for increased hypertension is sympathetic activity, and further complications of hypertension are heart failure, ischemic heart disease (IHD), stroke, and renal failure. Now, antihypertensive interventions have emerged as a global public health priority to reduce BP-related morbidity and mortality. Calcium channel blockers (CCB) are highly effective vasodilators. and the most common drugs used for managing hypertension and CVD. Cilnidipine, with both L- and N-type calcium channel blocking activity, is a promising 4th generation CCB. It causes vasodilation via L-type calcium channel blockade and inhibits the sympathetic nervous system (SNS) via N-type calcium channel blockade. Cilnidipine, which acts as a dual L/N-type CCB, is linked to a reduced occurrence of pedal edema compared to amlodipine, which solely blocks L-type calcium channels. The antihypertensive properties of cilnidipine are very substantial, with low BP variability and long-acting properties. It is beneficial for hypertensive patients to deal with morning hypertension and for patients with abnormal nocturnal BP due to exaggerated sympathetic nerve activation. Besides its BP-lowering effect, it also exhibits organ protection via sympathetic nerve inhibition and renin–angiotensin–aldosterone system inhibition; it controls heart rate and proteinuria. Reno-protective, neuroprotective, and cardioprotective effects of cilnidipine have been well-documented and demonstrated. © 2024 Journal of Association of Physicians of India. All rights reserved.